Crystalline fsemi-calcinous salt of [R-(R,R)]-2-(4-fluorophenyl)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrolo-1-enantanic acid (atorvastatin)

There are described novel crystalline forms of ÄR-(R*,R*)Ü-2-(4-fluorophenyl)- beta , delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-Ä(phenylamino)carbonylÜ-1H-pyr role-l-heptanoic acid hemi calcium salt designated Form II and Form IV which are characterized by their X-ray powder diffraction and/or s...

Full description

Saved in:
Bibliographic Details
Main Authors BRIGGS CHRISTOPHER A, HARASAWA KIKUKO, ICHIKAWA SHIGERU, NAKAGAWA SHINSUKE, MINOHARA KAZUO, WADE ROBERT A, JENNINGS REX ALLEN
Format Patent
LanguageEnglish
Polish
Published 28.02.2007
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:There are described novel crystalline forms of ÄR-(R*,R*)Ü-2-(4-fluorophenyl)- beta , delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-Ä(phenylamino)carbonylÜ-1H-pyr role-l-heptanoic acid hemi calcium salt designated Form II and Form IV which are characterized by their X-ray powder diffraction and/or solid state NMR, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia and hypercholesterolemia.
Bibliography:Application Number: PL19960324496